Vistagen Therapeutics (NASDAQ:VTGN) Third Quarter 2025 Results

Key Financial Results

• Net loss: US$14.1m (loss widened by 122% from 3Q 2024).
• US$0.46 loss per share (further deteriorated from US$0.22 loss in 3Q 2024).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Vistagen Therapeutics Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 31%. Earnings per share (EPS) also surpassed analyst estimates by 9.8%.

Looking ahead, revenue is forecast to grow 65% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's shares are up 5.7% from a week ago.

Risk Analysis

You still need to take note of risks, for example - Vistagen Therapeutics has 3 warning signs (and 1 which is a bit concerning) we think you should know about.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.